Humasis Co. Ltd. (KOSDAQ:205470)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,437.00
+39.00 (2.79%)
Aug 8, 2025, 3:30 PM KST
2.79%
Market Cap158.19B
Revenue (ttm)29.71B
Net Income (ttm)-33.78B
Shares Out113.15M
EPS (ttm)-296.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,612,490
Average Volume855,471
Open1,398.00
Previous Close1,398.00
Day's Range1,394.00 - 1,448.00
52-Week Range1,254.00 - 3,235.00
Beta0.08
RSI42.07
Earnings DateAug 14, 2025

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 2000
Employees 70
Stock Exchange KOSDAQ
Ticker Symbol 205470
Full Company Profile

Financial Performance

In 2024, Humasis's revenue was 25.41 billion, an increase of 83.79% compared to the previous year's 13.83 billion. Losses were -30.44 billion, -45.08% less than in 2023.

Financial Statements

News

There is no news available yet.